

Collateral damage: the impact on cancer outcomes of the COVID-19 pandemic

Amit Sud^{1*}, Michael Jones^{1*}, John Broggio^{2*}, Chey Loveday¹, Bethany Torr¹, Alice Garrett¹, David L. Nicol³, Shaman Jhanji^{4,5}, Stephen A. Boyce⁶, Phillip Ward⁴, Jonathan M. Handy⁴, Nadia Yousof⁷, James Larkin^{8,9}, Yae-Eun Suh¹⁰, Stephen Scott¹¹, Paul D.P. Pharoah¹², Charles Swanton^{13,14}, Christopher Abbosh^{13,14}, Matthew Williams^{15,16}, Georgios Lyratzopoulos^{2,17}, Richard Houlston^{1,18}, Clare Turnbull^{1,2,18}

*these authors contributed equally to the work

1. Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
2. National Cancer Registration and Analysis Service, Public Health England, Wellington House, London, UK.
3. Urology Unit, Royal Marsden NHS Foundation Trust, London, UK.
4. Department of Anaesthesia, Perioperative Medicine and Critical Care, Royal Marsden NHS Foundation Trust, London, UK
5. Division of Cancer Biology, Institute of Cancer Research, London, UK
6. Department of Colorectal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
7. Lung Cancer Unit, Royal Marsden NHS Foundation Trust, London, UK.
8. Skin and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.
9. Division of Clinical Studies, Institute of Cancer Research, London, UK.
10. Department of Clinical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
11. RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust, London, UK.
12. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
13. Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
14. Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London, UK.
15. Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, UK.
16. Computational Oncology Group, Imperial College London, London, UK.
17. Epidemiology of Cancer Healthcare and Outcomes (ECHO) Group, University College London, London, UK.
18. Department of Clinical Genetics, Royal Marsden NHS Foundation Trust, London, UK.

Supplementary Tables

Supplementary Table 1: Assumptions and parameters used to model cancer outcomes and COVID-19 infection.

Supplementary Table 2: Reduction in survival by tumour stage and age of diagnosis from delay to surgery of (a) 3 months (b) six months for 31 cancer types/subtypes.

Supplementary Table 3: Life years gained by cancer surgery under standard conditions by tumour stage and age of diagnosis for 31 cancer types/subtypes.

Supplementary Table 4: Estimated average life years gained per unit of healthcare resource from avoidance of 6 months delay for cancer surgery, by tumour stage and age of diagnosis for 31 cancer types/subtypes.

Supplementary Table 5: Attributable deaths in one year by tumour stage and age of diagnosis from delay to surgery of (a) 3 months (b) 6 months for 31 cancer types/subtypes.

Supplementary Materials (Excel): Full Models and parameters for analysis of outcomes for Cancer Surgery and community acquired COVID-19 infection.

Supplementary Table 1: Assumptions and parameters used to model cancer outcomes and COVID-19 infection.

Parameter, Location	Parameterisation, assumptions and justification	Value/Source for assumption/ parameter estimate(s)
Life expectancy and population structure		
P2	Life expectancy is that for the mid-age of the age-band, averaged for both sexes.	[1]
P7	5 year bands of population demography for England and China were used to account for differences in underlying population structure.	[2-4]
Cancer survival		
I_AL	<p>5-year cancer survival is based on data for England-2017, by tumour, stage and age in adult patients in whom major surgical resection was performed. Rarer tumour types, for which survival of surgical patients is not collected in PHE are not included.</p> <p>Justification: 5-year survival data are available by age-band and stage for all cancer diagnoses and for the subset in whom major resection is undertaken. By only using outcome data for patients in whom surgery was performed, we avoid potential upwards bias in survival from inclusion of stage 1 disease in which standard of care may be conservative (<i>i.e.</i> watch-and-wait). We also avoid potential downwards bias in survival from inclusion of poor prognosis stage 3 cancers, which are not eligible for surgery. Of note, for each tumour type, these data include all patients undergoing surgical resection and therefore account for outcomes in those with associated co-morbidities or which present as an emergency.</p>	[5]
I_AM	We used age-specific, stage-specific <i>net</i> survival 2013-2017 where available to give the most accurate estimates for cancer-specific survival. Net survival adjusts for background age-specific death rates to reflect cancer-specific mortality; generation of these estimates requires that at least 10 patients are alive at time of estimation and there are at least 2 deaths in the time either side of estimation. Where net survival could not be generated for a particular age-specific, stage-specific tumour cohort, where counts are >10, for the stratum we utilise the crude survival (simple Kaplan-Meier estimate), highlighting these as lower confidence estimates. For counts <10, we utilise the stage-specific survival for the adjacent age-band (younger if available). Net survival is censored at 100%	[6]
	<p>5-year survival 2013-2017 is used as a proxy for overall survival</p> <p>Justification: we reviewed availability of 10-year survival data, which would better reflect long-term survival, in particular for tumour types such as breast cancer. However, (i) data on 10-year survival is very limited for most cancers and not available by age-specific and stage-specific strata (ii) what there is not contemporaneous. Although there has been some changes in management for some cancers, for the majority of tumour types survival has not changed appreciably from that of the patients in 2013-2017.</p>	
	We based our analysis on the average mortality between sexes except for prostate, endometrial, ovarian and breast cancers.	
	<p>We considered cancer outcome as being binary: survival with normal life expectancy or fatal.</p> <p>Justification: this captures tumours upstaging during delay and the differences in survival between stages, without explicitly modelling proportions transitioning to a new stage.</p> <p>For any stage at presentation a proportion of patients will die from their cancer, despite surgery. The fatal proportion of each stratum is captured by the corresponding 5-year survival. We assume that for any stage stratum, deferral of surgery will cause a proportion to transition from non-fatal to fatal. This can be conceptualised as presence of fatal treatment-resistant micro-metastases. Delay of surgery will increase the likelihood of fatal treatment-resistant micro-metastases, thus resulting in fatality, despite surgery.</p> <p>This approach captures those that transition from ‘non-fatal’ to ‘fatal’ via either ‘between stage’ progression or ‘within stage progression’, including situations which a patient would have progressed from operable disease stage to inoperable disease stages (<i>e.g.</i> stage IV).</p>	
P1	Reduction on overall survival is defined by a constant hazard ratio over five years.	[7-17]

	<p>Justification: Although there are a multitude of mathematical models of cancer growth and spread, it remains unclear how these faithfully model surgical intervention, clinical staging, metastasis and outcome. Experimentally-derived estimates to quantify the impact of delay on survival would have constituted the optimal type of evidence to inform assumptions in the model, but those do not exist as randomised trials comparing non-delayed versus dramatically delayed surgery would be clearly unethical. We thus sought to obtain metrics of tumour transition from non-fatal to fatal data from clinical studies of survival in cohorts of patients in whom treatment was delayed.</p> <p>A number of retrospective observational studies have examined the effect of diagnostic and/or treatment delay on cancer outcome, many providing data by tumour stage. Limitations of these studies include (i) historical patient cohorts when treatments were less effective compared to the present day (ii) selection bias, as patients with the poorest prognosis experience the more timely management (also termed ‘confounding by indication’, ‘waiting time paradox’ or ‘sicker-quicker’ phenomena), which can mask true association between delay and survival when examining only short delay periods. Another complication of these studies is how staging relates to delay. For some cancers, tumour stage was assigned following surgery, not at time of diagnosis. Thus ‘within-stage’ progression is captured, but there may be underestimation of effect due to failure to capture ‘between-stage’ progression.</p> <p>We reviewed the literature to identify studies of delay in treatment for which there was follow up for ≥ 5 years comprising either hazard ratios or % survival. We identified 11 suitable studies. We restricted analysis to tumour types for which multiple survival comparisons were available and multiple stages were included (colorectal cancer, breast cancer and bladder cancer). Studies did not present trend HRs, so we estimated these by linear regression, using the median delay associated with each HR, or if medians were not presented we used the mid-point, except for the first (baseline) group where we assumed the median occurred at 2/3 the width of the interval (which was consistent with studies that reported a median and interval), and for the last open-ended group we assumed the median occurred at the lower boundary plus half the width of the previous strata.</p>	
P1	<p>The per day hazard ratio for tumour transition is independent of disease stage.</p> <p>Justification: Although we had hypothesised that tumour volume and tumour ‘maturity’ would influence rate of metastatic growth, review of reported observational studies revealed little evidence of clear per stage effect on per day HRs.</p>	
P21 4_B	<p>The per day hazard ratio for tumour transition is fixed for each of tumours of low, medium and high aggressiveness,</p> <p>Justification: We used Stage 2 disease behaviour as a proxy for overall tumour aggressiveness (as this excludes the indolent entities which may be included in stage 1 and disregards artefactual bias of the distribution of asymmetric stage-at-ascertainment). We arbitrarily assign low, medium and high aggressiveness as 5 year survival in Stage 2 of $>90\%$, $50-90\%$ and $<50\%$ respectively. We classified cancers as being of low (5-year survival $>90\%$), moderate ($90-50\%$) or high ($<50\%$) aggressiveness.</p> <p>Our useable observational studies from 3 tumour types reveal clear differences between breast cancer compared to bladder and colorectal cancer. There are no relevant observational data available for most tumour types, in particular those of poor outcomes. We calculated a weighted average for the HR per day delay in treatment based on the number of patients in each study for (i) breast cancer (ii) colorectal and bladder cancer. We apply the per day hazard ratio from breast cancer to tumours of low aggressiveness, and the weighted average for bladder and colorectal for tumours of moderate aggressiveness (The 5 year survival figures for stage 2 breast, colorectal and bladder cancer are 93.5%, 88.5% and 54.0%). Because we have no observational data upon which to base a per day hazard ratio for high aggressiveness tumours (eg oesophageal, gastric), we use the same transition HR from the moderate group; this is likely to be a conservative assumption.</p> <p>Example: For 60-69 year olds with Stage 2 kidney cancer given standard surgery provision, the 5 year survival is 88.9%. Hence, at time of diagnosis, 11.15% of these individuals had disease that was already fatal despite surgery. This corresponds to a hazard rate of death of 2.34% per year. Kidney cancer is of moderate aggressiveness, for which we assign a HR is assumed to be 1.0056/day (based on values for bladder and colorectal cancers). For a 6 month (183 day) delay in treatment the new annual death rate is estimated to be $2.34\% * \text{EXP}(183 * \log(1.0056))$. This equates to a 5-year survival of 72.2% (or 27.9% fatality). Thus, (27.9%-11.2%) 16.8% of individuals who had non-fatal disease at diagnosis, transition to having fatal disease during the period of delay.</p>	
Nosocomial COVID-19 infection in cancer patients		

P5	Likelihood of nosocomial COVID-19 infection is a function of a per day rate of infection. There is a current rate of nosocomial infection that is uniform nationally.	[10%]
P6	There may still be significant nosocomial infection if surgery is performed after a period of delay. This rate of nosocomial infection is also uniform nationally.	[5%]
P7 1_R	Mortality from nosocomial COVID-19 infection from admission for surgery and SACT is the same as for that reported in Wuhan for non-ICU hospital admission. Justification: There are currently no age-stratified published data available for COVID-19 mortality from unbiased community-based ascertainment. As these infections will have the characteristics of community-based rather than hospital-ascertained infection, this is likely conservative (i.e. we may over estimate nosocomial mortality by applying these to infection that is not severe or critical).	[18]
1_AU	Where the benefit of surgery performed under current conditions (i.e. accounting for COVID-related mortality) is less than under delayed conditions (when COVID-related mortality is reduced due to lower nosocomial infection), the attributable deaths and LYG are set at zero for the summed measures regarding impact of delay.	
	No risk of community acquired COVID-19 infection is included.	
Adjuvant cancer therapy		
	Administration of adjuvant radiotherapy is continued using standard/modified protocols resulting in no detriment to survival. Justification: Staff and resources for delivery of adjuvant radiotherapy are largely distinct from those required for acute COVID-related admission. Thus, we have not included modification to radiotherapy in our model, although we recognise that withholding of radiotherapy would have an impact on 5 year survival, whilst high dosage protocols may contribute to hospital-related COVID-19 infection and mortality.	
	Administration of adjuvant endocrine therapy and oral targeted therapies are continued as per standard protocols resulting in no detriment to survival.	
	A priori mitigation by non-surgical, endocrine-only management of tumours such as ER-positive breast cancer and prostate cancer is not included in the current version of the model.	
P4	Survival benefit of SACT varies by stage but is uniform across tumour types Justification: Expert oncological estimates combined with the literature were used. This reflects a simplistic estimate for multiple metrics that are highly complex to estimate as: (i) regimens of adjuvant chemotherapy have evolved since the period to which our 5-year survival data pertain, (ii) selection of agents and evaluation of patient eligibility for chemotherapy regimens vary nationally, (iii) clinical trial data reference the efficacy of such treatments in selected patient groups, rather than the real-world patient population.	[5% (Stage 1), 7.5% (Stage 2), 10% (Stage 3)]
P27 4_J	Adjuvant SACT is a uniform number of rounds per tumour-type-stage, each necessitating two hospital attendances each of a half-day (evaluation and administration). Each attendance incurs a risk of hospital-acquired COVID-19 infection as per the daily likelihood.	
P3	If infected, COVID-related mortality during SACT increases age-specific COVID-related mortality due to immunocompromise.	[2-fold] [18]
1_AB-AC 1_AF-AG	Systemic anti-cancer therapy is administered where the survival benefit exceeds the additional risk of mortality from COVID. This decision is applied within the model and applied to the survival metrics for each tumour age/stage group for both 'current' and 'post-delay' SACT delivery.	
Cancer surgery and resourcing		
5_E	All patients with a given tumour stage have a single standard open operation. Laparoscopic and stereotactic procedures are not performed on account of risk of aerosol generation. No complex reconstruction is performed.	[19]

	Justification: whilst a single operation per tumour sub-stage is over-simplification, given discontinuation of many approaches this assumption is unlikely to cause sizeable mis-estimation of surgical time resource. Current guidance from the Royal College of Surgeons England has recommended specific approaches, including avoidance of laparoscopic, stereotactic and robotic surgery, on account of increased likelihood of aerosol generation.	
P18	Operations are uncomplicated and surgical lists comprise a uniform number of productive theatre hours per 12 hour shift. Ward care is uncomplicated with no delay to discharge. Postoperative ICU is allocated as per requirement, not as a precautionary measure.	[10 hours]
P23-25	Theatre time, ICU stay and ward stay are standard for a given operation as per the median of values from 3 large surgical oncology centres. Day-case surgery is counted as a half day of hospital admission.	
P18	A theatre is staffed by a 1 consultant surgeon, 1 consultant anaesthetist and 3 theatre staff (ODP, theatre nurses), as per the median of values from 3 large surgical oncology centres. There is a single anaesthetist per theatre: surgical durations allow for anaesthetic time (with ODP support).	
P19	An ICU bed is staffed by 1:1 by an ICU nurse and 1:4 by an anaesthetist, as per the median of values from 3 large surgical oncology centres.	
P20	A surgical/medical ward bed is staffed 1:4 by a ward nurse, 1:10 by a junior doctor and 1:20 by a senior doctor, as per the median of values from 3 large surgical oncology centres.	
	We cost resource using 12-hour shifts of direct medical/nursing care. One healthcare resource unit (HCRU) is one 12-hour shift for a standard staff member (theatre nursing staff, ward nursing staff and junior doctors).	
P15	Salaries for senior doctors (surgeons, anaesthetists, physicians) are approximately double those of theatre nursing staff, ward nursing staff and junior doctors. These staffing groups were up-weighted in the resource-costing analysis.	[2-fold]
P16	ICU provision is in highest competition. Anaesthetists and ICU nurses are most limited and are up-weighted in the resource-costing analysis.	[2-fold]
COVID-19 outcomes		
P8	Age distribution of COVID-19 cases in the community resembles that of Wuhan. Justification: detailed age-specific UK breakdown of community cases has not yet been provided. Hence we applied the age distribution of cases admitted in Wuhan and adjusted for differences in 10 band demographic population structure between China and England.	[2, 3, 18]
P9	The likelihood of a community case being admitted to hospital is age specific and resembles that in Wuhan. Justification: detailed age-specific UK likelihoods of hospital admission have not yet been provided.	[18]
P10	A fixed proportion of hospital admissions are admitted to ICU and resembles that in Lombardy.	[16%][20]
P11	Age distribution of COVID-19 cases admitted to ICU resembles that reported up to 17/4/20 by ICNARC. Justification: these data best reflect ICU admittance practice in England. Due to exclusion of cases in which prolonged ventilation was required, this dataset is released caveated for likely downward bias of ICU occupation and upward bias of outcomes, and is thus conservative regarding resource requirement for COVID-19 management.	[21]
P13	For individuals with critical COVID-19 infection non hospitalisation would result in 0% survival.	
	For individuals with severe COVID-19 infection, in the absence of unbiased prospective data, we utilised a conservative figure that survival would be 75% of that of the age-specific rate for those hospitalised.	
P14	Bed occupancy for critical (ICU) COVID-19 admission comprises 5 ICU days and 5 non-ICU days.	[4, 18, 21, 22]

	Justification: estimates based on ICNARC-reported ICU occupancy and reports from Wuhan of post-ICU bed occupancy for critical cases, along with averages of best available evidence from practice in England for viral pneumonia in 2019.	
P14	Bed occupancy for severe (non-ICU) COVID-19 admissions is on average 8 ward days. Justification: estimates based on averages of best available evidence from practice in England for viral pneumonia in 2019.	[4, 18, 21, 22]

Supplementary Table 2: Reduction in survival by tumour stage and age of diagnosis from delay to surgery of (a) 3 months (b) six months for 31 cancer types/subtypes.

Supplementary Table 2a	Stage	30-39 v	40-49 v	50-59 v	60-69 v	70-79 v	80+ v
Bladder	1	6.3%*	6.3%*	11.1%	7.3%	8.7%	9.5%
	2	17.6%*	17.5%	14.4%	13.4%	10.5%	12.6%
	3	18.2%*	18.1%*	16.1%	16.8%	14.7%	13.7%
Breast (ER+, HER2-)	1	0.6%	0.2%	-0.5%	-1.6%	-0.9%	-0.4%
	2	2.5%	1.1%	0.7%	-0.6%	-2.6%	-0.3%
	3	6.1%	3.6%	3.8%	3.3%	2.3%	1.0%
Breast (ER-, HER2-)	1	2.7%	1.8%	2.1%	0.1%	0.6%	2.6%
	2	5.9%	5.4%	4.8%	3.7%	4.2%	7.6%
	3	8.6%*	9.8%	9.3%	8.4%	8.0%	8.1%*
Breast (HER2+)	1	0.1%	0.3%	0.1%	-0.7%	-0.3%	2.4%
	2	1.8%	1.3%	1.2%	0.4%	-0.5%	4.4%
	3	5.0%	3.0%	4.0%	3.1%	4.9%	6.9%
Breast (other)	1	1.3%	0.5%	-0.4%	-1.5%	-0.9%	-0.4%
	2	2.9%	1.5%	1.2%	0.1%	-1.6%	-0.3%
	3	6.7%	4.7%	4.6%	3.9%	3.4%	4.9%
Cervix	1	1.9%	1.9%	0.6%	7.1%	6.1%*	14.7%*
	2	7.2%*	17.0%*	7.1%*	10.6%	9.5%*	12.1%*
	3	11%*	10.9%*	10.4%*	9.3%*	7.2%*	7.0%*
Colon and rectosigmoid junction	1	0.8%	1.8%	1.5%	0.7%	-1.6%	-3.0%
	2	6.6%	6.3%	5.4%	5.4%	5%	-0.1%
	3	13%	12.5%	12.2%	11.2%	11.3%	11.6%
Glioblastoma	N/A	13.9%	7.9%	4.4%	2.5%	2.8%*	0.3%*
Hypopharynx	N/A	18.5%*	18.5%*	17.3%	16.2%	13.8%	14%*
Kidney	1	0.8%	0.9%	2.1%	1.5%	-0.8%	-2.7%
	2	5.1%*	6.8%	4.3%	6.0%	4.4%	9.7%
	3	8.0%*	9.7%	10.7%	10%	8.8%	7.5%
Larynx	1	4.4%*	6.4%	7.5%	6.3%	3.3%	6.4%
	2	12.8%*	12.7%*	8.2%*	13.7%	13.8%	16.3%*
	3	15.5%*	15.4%*	16.8%	15.4%	14.1%	12.3%*
Liver	1	12%*	12%*	16.3%	16.8%	16.8%	13.6%*
	2	13.5%*	13.5%*	18.4%	17.9%	17.1%	16.1%*
	3	18.5%*	18.4%*	18.3%*	17.6%	16.2%*	14.3%*
Lung (non-small cell)	1	2.0%	5.6%	10.5%	11.3%	12%	8.3%
	2	13.9%*	15.7%	16.1%	16.1%	14.9%	14.9%
	3	18.3%*	18.2%	18.1%	16.6%	14.9%	11.8%
Lung (small cell)	1	15.4%*	15.3%*	15.1%*	17.8%	16.9%*	15.3%*
	2	18.2%*	18.1%*	17.6%*	17%*	15%*	14.7%*
	3	15.1%*	15%*	14.7%*	15.8%*	10.9%*	10.2%*
Melanoma of skin	1	0.4%	1.0%	0.1%	0.4%	-0.1%	0.8%
	2	8.1%	9.2%	9.9%	11.9%	11.1%	15.4%
	3	12.5%	13.4%	13.6%	14.7%	12.3%	15%
Nasal cavity and sinus	N/A	10.6%*	14.3%*	16%*	17.6%	17.5%	16.6%*
Nasopharynx	N/A	9.1%*	9.1%*	15%*	17.9%*	17.3%*	12.8%*
Oesophagus	1	14%*	13.8%	12.6%	11.8%	9.7%	13.1%*
	2	18.2%*	18.1%*	17%	15.9%	13.7%	14.5%*
	3	17.3%*	18.4%	17.5%	16.9%	14.5%	13.3%*
Oral cavity	N/A	10.4%	13.9%	14.5%	14.7%	15.3%	14.5%
Oropharynx	N/A	7.3%	10.1%	10.3%	12.3%	13.4%	16.0%
Ovary	1	1.7%	2.7%	4.1%	3.8%	3.9%	-1.4%
	2	6.7%*	11%	12.4%	12.6%	13.8%	16.6%
	3	13.9%	18.2%	18.4%	17.7%	16.5%	13.2%
Pancreas	1	1.0%*	3.5%*	4.5%*	4.8%	7.5%*	11.6%*
	2	9.8%*	18%*	16.4%	14.6%	12.8%	14.2%*
	3	10.3%*	10.2%*	14.1%*	16.9%*	14.8%*	13.1%*
Prostate	1	0.6%*	0.5%	-0.3%	-0.7%	-0.2%	5.9%
	2	0.0%*	-0.1%	-0.3%	-0.7%	-1.6%	6.9%*
	3	0.0%*	-0.1%	-0.3%	-0.7%	-1.6%	7.5%*
Rectal	1	2.4%	2.7%	1.0%	0.8%	-1.4%	-1.0%
	2	7.2%	5.6%	5.1%	5.6%	4.1%	0.8%
	3	10.4%	11.3%	9.1%	8.4%	7.8%	9.4%
Renal pelvis and ureter	1	3.2%*	3.1%*	3.9%*	7%	11.2%	7.4%
	2	9.5%*	9.5%*	9.1%*	14%	13.9%	4.1%
	3	13.1%*	13.1%*	13.6%*	17.9%	17.5%	15.3%
Salivary glands	N/A	3.9%	9.9%	6.1%	11.1%	11.3%	14.7%
Stomach	1	4.7%*	7.3%*	12.3%	7.5%	3.6%	-3.4%
	2	18.5%*	11.8%*	16.6%	16.1%	13.4%	6.9%
	3	16.3%*	18.2%	18%	16.9%	14.9%	13.6%
Testis	1	0.1%	0.0%	0.0%	-0.8%	0.3%*	0.3%*
	2	0.7%*	1.2%*	0.5%*	1.5%*	0.0%*	0.1%*
	3	3.5%*	1.7%*	3.6%*	4%*	2.1%*	2.1%*
Urethra	N/A	18%	18%*	17.6%*	16.7%*	15.3%	15.1%*
Uterus	1	1.2%	2.1%	2.2%	3.4%	4.3%	1.0%
	2	5.2%*	7.4%	7.5%	10.9%	14.2%	14.2%
	3	3.9%*	13.7%	15.1%	17.8%	17.9%	17.4%
Vulva	1	1.0%*	1.8%	5%	5.7%	9.9%	16.8%
	2	13.9%*	13.9%*	15.7%*	14.0%*	16%*	16.4%*
	3	15.8%*	14.9%*	14.7%*	18.1%	17.8%	16.2%*

* indicates strata estimates of lower confidence whereby crude rather than net survival estimates were applied.

Supplementary Table 2b	Stage	30-39 v	40-49 v	50-59 v	60-69 v	70-79 v	80+ v
Bladder	1	15.8%*	15.8%*	26.3%	18.4%	21.7%	23.6%
	2	35.9%*	35.8%	32.4%	31.1%	27.4%	28.9%
	3	35.9%*	35.8%*	34.5%	33.3%	30.6%	28%
Breast (ER+, HER2-)	1	1.5%	0.6%	-0.4%	-1.6%	-0.9%	-0.4%
	2	5.8%	2.8%	2.4%	0.6%	-1.6%	-0.3%
	3	13.4%	8.2%	9.1%	9.0%	8.6%	5.1%
Breast (ER-, HER2-)	1	6.2%	4.3%	5.3%	2.1%	2.5%	6.3%
	2	13%	12.2%	11.2%	9.8%	12%	16.4%
	3	18.2%*	19.8%	19.3%	18.2%	17.5%	16.1%*
Breast (HER2+)	1	0.4%	0.9%	0.9%	0.3%	0.5%	5.8%
	2	4.2%	3.1%	3.3%	2.8%	2.9%	10.1%
	3	11.3%	7.0%	9.6%	8.6%	13.2%	15.9%
Breast (other)	1	3.1%	1.5%	-0.3%	-1.4%	-0.9%	-0.4%
	2	6.7%	3.7%	3.5%	2.2%	0.5%	-0.3%
	3	14.6%	10.5%	10.8%	10.2%	10.6%	12.7%
Cervix	1	4.9%	5.2%	1.9%	18.3%	16.7%*	32.9%*
	2	17.9%*	35.6%	17.9%*	25.6%	23.8%*	29.1%*
	3	26.2%*	26.1%*	25.5%*	24.1%*	21.6%*	20.7%*
Colon and rectosigmoid junction	1	2.1%	4.9%	4.5%	2.9%	-1.6%	-3.0%
	2	16.6%	15.9%	14%	14.6%	14.6%	4.4%
	3	29.9%	29.1%	28.9%	27.8%	28.5%	28.1%
Glioblastoma	N/A	20.3%	9.9%	5.1%	2.7%	3.1%*	0.3%*
Hypopharynx	N/A	34.3%*	34.2%*	29.5%	27.7%	22.8%	23.6%*
Kidney	1	2.1%	2.6%	5.9%	5%	0.3%	-2.7%
	2	13.2%*	17.0%	11.5%	16%	13.4%	25.5%
	3	19.7%*	23.5%	25.6%	24.7%	23%	21.4%
Larynx	1	11.5%*	16.2%	19%	16.8%	10.9%	19.3%
	2	29.5%*	29.4%*	20.5%*	31.4%	31.7%	31.4%*
	3	33.9%*	33.7%*	35.1%	33.4%	31.1%	19.6%*
Liver	1	28.1%*	28%*	34.9%	35.1%	34%	31.3%*
	2	30.9%*	30.8%*	34.2%	34.8%	33.6%	31.1%*
	3	33%*	32.9%*	32.7%*	30.5%	26.9%*	23%*
Lung (non-small cell)	1	5.4%	14.3%	25.4%	27.3%	29%	23.1%
	2	31.5%*	34.1%	34.5%	33.7%	30.6%	29.1%
	3	35.7%*	35.6%	33.8%	28.9%	26.4%	18.5%
Lung (small cell)	1	33.7%*	33.7%*	33.4%*	34.9%	34%*	32.4%*
	2	35.9%*	35.8%*	35.2%*	30.9%*	27.2%*	26.2%*
	3	22.8%*	22.8%*	22.4%*	26.3%*	15.8%*	14.7%*
Melanoma of skin	1	1.1%	2.5%	0.4%	1.2%	0.2%	2.7%
	2	19.9%	22.5%	23.9%	28.1%	26.8%	33.8%
	3	29%	30.7%	31.2%	32.9%	29.9%	30.8%
Nasal cavity and sinus	N/A	25.4%*	32.2%*	34.6%*	35.4%	34.1%	29.6%*
Nasopharynx	N/A	22.2%*	22.2%*	33.2%*	35.3%*	34.4%*	30.5%*
Oesophagus	1	31.6%*	31.4%	29.6%	28.8%	25.2%	29.6%*
	2	35.8%*	35.7%*	35.1%	33.5%	30.5%	27.7%*
	3	35.8%*	34.1%	30.2%	31.2%	25.5%	23.9%*
Oral cavity	N/A	25%	31.5%	32.4%	32.9%	33.7%	32.7%
Oropharynx	N/A	18.2%	24.5%	25.3%	29.5%	31%	31.2%
Ovary	1	4.6%	7.1%	10.8%	10.3%	11.1%	-1.4%
	2	16.8%*	26.2%	28.9%	29.4%	31.6%	34.7%
	3	31.4%	35.9%	33.7%	31.2%	28.1%	20.2%
Pancreas	1	1%*	9.5%*	12.7%*	15.1%	21%*	28%*
	2	23.7%*	35.8%*	26.8%	23%	20.3%	25.2%*
	3	24.8%*	24.7%*	32.1%*	32.4%*	29.7%*	22.8%*
Prostate	1	1.4%*	1.4%	-0.3%	-0.7%	1.5%	14.8%
	2	0.0%*	-0.1%	-0.3%	-0.7%	-1.6%	16.3%*
	3	0.0%*	-0.1%	-0.3%	-0.7%	-1.6%	17.1%*
Rectal	1	6.5%	7.4%	3.8%	5.3%	0.1%	1.9%
	2	18%	14.5%	13.9%	16.7%	15.8%	6.1%
	3	24.9%	26.9%	22.9%	22.6%	23%	25.2%
Renal pelvis and ureter	1	8.3%*	8.2%*	10.4%*	18.2%	27.5%	21.1%
	2	23.1%*	23.1%*	22.4%*	31.9%	31.8%	14.2%
	3	30.1%*	30%*	31.1%*	35%	32.6%	32.9%
Salivary glands	N/A	10.2%	24.1%	16.2%	27.5%	28.6%	31.5%
Stomach	1	12.2%*	18.5%*	29.1%	20.9%	12.5%	-3.4%
	2	34.9%*	27.8%*	34.9%	33.6%	30.4%	20.2%
	3	34.9%*	32.2%	32.9%	31.5%	27.3%	25.4%
Testis	1	0.4%	0.1%	0.3%	-0.8%	3.0%*	3.9%*
	2	1.8%*	3%*	1.7%*	4.8%*	3.3%*	3.3%*
	3	8.1%*	4.2%*	8.9%*	10.7%*	8.6%*	8.3%*
Urethra	N/A	31.2%	31.1%*	30.7%*	29.5%*	29.6%	28.2%*
Uterus	1	3.3%	5.6%	6.0%	9.4%	12.3%	5.6%
	2	13.2%*	18.4%	18.9%	26.3%	32.2%	32.2%
	3	10.2%*	31.1%	33.3%	35.7%	32.7%	32.9%
Vulva	1	1.0%*	4.8%	12.9%	14.8%	24.3%	35.2%
	2	31.5%*	31.5%*	34.2%*	31.8%*	34.4%*	27.7%*
	3	34.3%*	33%*	32.8%*	31.9%	31.8%	26.8%*

* indicates strata estimates of lower confidence whereby crude rather than net survival estimates were applied.

Supplementary Table 3: Life years gained by cancer surgery under standard conditions by tumour stage and age of diagnosis for 31 cancer types/subtypes.

	Stage	30-39 v	40-49 v	50-59 v	60-69 v	70-79 v	80+ v
Bladder	1	23.4*	18.7*	12.6	9.6	5.7	2.9
	2	1.2*	0.9	0.8	0.6	0.4	0.2
	3	1.1*	0.9*	0.8	0.4	0.3	0.1
Breast (ER+, HER2-)	1	20.4	16.5	12.6	8.8	5.4	2.8
	2	19.0	15.9	12.1	8.5	5.3	2.8
	3	16.0	14.5	10.7	7.3	4.4	2.5
Breast (ER-, HER2-)	1	18.9	15.6	11.5	8.3	5.2	2.5
	2	16.2	13.2	10.2	7.2	3.9	1.8
	3	13*	8.2	6.6	4.9	2.4	0.9*
Breast (HER2+)	1	20.7	16.4	12.3	8.6	5.3	2.5
	2	19.6	15.9	11.9	8.3	4.9	2.3
	3	17.0	14.9	10.6	7.4	3.8	1.7
Breast (other)	1	19.9	16.3	12.5	8.8	5.4	2.8
	2	18.7	15.7	11.9	8.3	5.1	2.8
	3	15.4	13.8	10.3	7.1	4.1	2.0
Cervix	1	8.4	6.7	5.2	3.2	2.0*	0.8*
	2	7.7*	4.3	4.6*	2.9	1.8*	0.9*
	3	7.0*	5.6*	4.2*	2.9*	1.8*	0.9*
Colon and rectosigmoid junction	1	3.3	2.6	2.0	1.4	0.9	0.5
	2	3.0	2.4	1.8	1.3	0.8	0.4
	3	2.5	2.0	1.5	1.1	0.6	0.3
Glioblastoma	N/A	0.8	0.3	0.1	0.0	0*	0*
Hypopharynx	N/A	1.2*	1*	0.6	0.4	0.2	0.1*
Kidney	1	6.4	5.1	3.8	2.7	1.7	0.9
	2	3.3*	2.5	2.0	1.3	0.8	0.4
	3	3.1*	2.4	1.7	1.2	0.8	0.4
Larynx	1	2.9*	2.2	1.6	1.2	0.8	0.4
	2	2.4*	1.9*	1.6*	0.9	0.6	0.2*
	3	2*	1.6*	1.1	0.8	0.4	0.1*
Liver	1	2.3*	1.8*	1.1	0.7	0.4	0.3*
	2	2.2*	1.7*	0.8	0.6	0.4	0.2*
	3	1.2*	1*	0.7*	0.5	0.3*	0.1*
Lung (non-small cell)	1	2.9	2.1	1.4	1.0	0.6	0.3
	2	2.1*	1.6	1.1	0.7	0.4	0.2
	3	1.5*	1.2	0.8	0.5	0.3	0.1
Lung (small cell)	1	2*	1.6*	1.2*	0.6	0.4*	0.2*
	2	1.6*	1.3*	1*	0.5*	0.3*	0.2*
	3	0.7*	0.6*	0.4*	0.4*	0.1*	0.1*
Melanoma of skin	1	34.6	27.4	20.9	14.6	9.1	4.6
	2	9.0	7.0	5.2	3.4	2.1	0.9
	3	8.0	6.1	4.5	2.9	1.8	0.7
Nasal cavity and sinus	N/A	4.7*	3.3*	2.3*	1.3	0.8	0.3*
Nasopharynx	N/A	4.9*	3.9*	2.4*	1.3*	0.8*	0.5*
Oesophagus	1	1.3*	1.0	0.8	0.5	0.4	0.1*
	2	0.9*	0.8*	0.6	0.4	0.3	0.1*
	3	1.1*	0.6	0.4	0.3	0.2	0.1*
Oral cavity	N/A	8.5	6.1	4.5	3.0	1.8	0.9
Oropharynx	N/A	7.6	5.7	4.2	2.7	1.4	0.6
Ovary	1	10.2	8.0	5.9	4.1	2.5	1.4
	2	9.3*	6.7	4.8	3.3	1.9	0.8
	3	1.9	1.1	0.7	0.4	0.2	0.1
Pancreas	1	0.0*	1.4*	1.0*	0.7	0.4*	0.2*
	2	1.5*	0.8*	0.3	0.2	0.1	0.1*
	3	1.5*	1.2*	0.8*	0.4*	0.2*	0.1*
Prostate	1	3.5*	2.8	2.1	1.5	0.9	0.3
	2	3.6*	2.8	2.1	1.5	0.9	0.3*
	3	3.6*	2.8	2.1	1.5	0.9	0.3*
Rectal	1	3.2	2.5	2.0	1.3	0.9	0.4
	2	2.9	2.4	1.8	1.2	0.7	0.4
	3	2.7	2.1	1.7	1.1	0.7	0.3
Renal pelvis and ureter	1	5.0*	4.0*	2.9*	1.9	1.0	0.6
	2	4.3*	3.5*	2.6*	1.6	0.9	0.6
	3	3.9*	3.1*	2.3*	1.1	0.6	0.4
Salivary glands	N/A	8.2	5.7	4.7	2.8	1.6	0.7
Stomach	1	1.9*	1.4*	0.9	0.7	0.5	0.3
	2	0.9*	1.2*	0.7	0.5	0.3	0.2
	3	1.2*	0.6	0.5	0.4	0.2	0.1
Testis	1	17.3	13.8	10.4	7.3	4.2*	2.1*
	2	16.9*	13.3*	10.2*	6.7*	4.1*	2.1*
	3	6.5*	5.6*	3.8*	2.5*	1.5*	0.8*
Urethra	N/A	1.1	0.8*	0.6*	0.4*	0.3	0.2*
Uterus	1	8.5	6.7	5.1	3.4	2.1	1.1
	2	8*	6.1	4.6	2.9	1.6	0.8
	3	8.2*	5.1	3.6	2.0	1.0	0.5
Vulva	1	0.2*	13.5	9.6	6.6	3.7	1.4
	2	5.4*	4.3*	3*	2.2*	1.2*	0.3*
	3	5.0*	4.2*	3.1*	1.3	0.8	0.3*

Supplementary Table 4: Estimated average life years gained per unit of healthcare resource from avoidance of 6 months delay for cancer surgery, by tumour stage and age of diagnosis for 31 cancer types/subtypes.

	Stage	30-39	40-49	50-59	60-69	70-79	80+
Bladder	1	4.11*	3.28*	4.14	2.02	1.48	0.83
	2	0.71*	0.57	0.39	0.26	0.14	0.08
	3	0.71*	0.57*	0.41	0.28	0.16	0.07
Breast (ER+, HER2-)	1	0.31	0.1	-0.04	-0.14	-0.05	-0.01
	2	1.22	0.47	0.3	0.05	-0.09	-0.01
	3	2.8	1.37	1.15	0.79	0.47	0.14
Breast (ER-, HER2-)	1	1.29	0.72	0.67	0.19	0.14	0.18
	2	2.71	2.03	1.41	0.86	0.66	0.46
	3	3.8*	3.3	2.43	1.60	0.95	0.45*
Breast (HER2+)	1	0.09	0.16	0.12	0.03	0.03	0.16
	2	0.88	0.52	0.42	0.25	0.16	0.29
	3	2.36	1.16	1.2	0.76	0.72	0.45
Breast (other)	1	0.66	0.25	-0.03	-0.13	-0.05	-0.01
	2	1.41	0.62	0.44	0.19	0.02	-0.01
	3	3.04	1.76	1.36	0.90	0.58	0.36
Cervix	1	0.43	0.36	0.1	0.67	0.38*	0.39*
	2	1.56*	2.47	0.94*	0.94	0.54*	0.34*
	3	2.28*	1.81*	1.34*	0.89*	0.49*	0.24*
Colon and rectosigmoid junction	1	0.07	0.13	0.09	0.04	-0.01	-0.01
	2	0.55	0.42	0.28	0.21	0.13	0.02
	3	1.0	0.77	0.58	0.39	0.25	0.13
Glioblastoma	N/A	0.72	0.28	0.11	0.04	0.03*	0*
Hypopharynx	N/A	0.91*	0.72*	0.47	0.31	0.16	0.08*
Kidney	1	0.14	0.13	0.23	0.14	0.01	-0.02
	2	0.47*	0.48	0.25	0.24	0.12	0.12
	3	0.70*	0.67	0.55	0.37	0.21	0.1
Larynx	1	0.36*	0.41	0.36	0.22	0.09	0.08
	2	0.92*	0.74*	0.39*	0.42	0.26	0.13*
	3	1.00*	0.8*	0.63	0.42	0.24	0.08*
Liver	1	0.83*	0.66*	0.62	0.44	0.26	0.13*
	2	0.91*	0.73*	0.61	0.43	0.26	0.12*
	3	0.97*	0.78*	0.58*	0.38	0.21*	0.09*
Lung (non-small cell)	1	0.16	0.34	0.45	0.34	0.22	0.09
	2	0.93*	0.8	0.62	0.42	0.24	0.12
	3	1.05*	0.84	0.6	0.36	0.2	0.07
Lung (small cell)	1	1.00*	0.79*	0.6*	0.43	0.26*	0.13*
	2	1.06*	0.84*	0.63*	0.39*	0.21*	0.1*
	3	0.67*	0.54*	0.4*	0.33*	0.12*	0.06*
Melanoma of skin	1	0.39	0.71	0.07	0.18	0.02	0.13
	2	2.07	1.87	1.51	1.24	0.73	0.48
	3	3.03	2.56	1.96	1.45	0.81	0.43
Nasal cavity and sinus	N/A	1.47*	1.49*	1.21*	0.87	0.52	0.23*
Nasopharynx	N/A	1.29*	1.03*	1.16*	0.86*	0.52*	0.24*
Oesophagus	1	0.56*	0.45	0.32	0.22	0.12	0.07*
	2	0.64*	0.51*	0.38	0.25	0.14	0.07*
	3	0.64*	0.48	0.32	0.23	0.12	0.06*
Oral cavity	N/A	2.61	2.62	2.04	1.45	0.92	0.46
Oropharynx	N/A	1.58	1.7	1.33	1.08	0.70	0.37
Ovary	1	0.48	0.59	0.68	0.45	0.30	-0.02
	2	1.76*	2.18	1.82	1.3	0.86	0.49
	3	0.83	0.76	0.54	0.35	0.19	0.07
Pancreas	1	0.02*	0.14*	0.14*	0.12	0.1*	0.07*
	2	0.43*	0.52*	0.29	0.18	0.1	0.06*
	3	0.45*	0.36*	0.35*	0.25*	0.14*	0.06*
Prostate	1	0.05*	0.04	-0.01	-0.01	0.01	0.07
	2	0*	0	-0.01	-0.01	-0.02	0.08*
	3	0*	0	-0.01	-0.01	-0.02	0.08*
Rectal	1	0.22	0.2	0.08	0.07	0	0.01
	2	0.6	0.39	0.28	0.23	0.14	0.03
	3	0.83	0.72	0.46	0.32	0.2	0.11
Renal pelvis and ureter	1	0.43*	0.34*	0.33*	0.4	0.37	0.15
	2	1.21*	0.96*	0.71*	0.7	0.43	0.1
	3	1.57*	1.25*	0.98*	0.77	0.44	0.23
Salivary glands	N/A	0.88	1.67	0.85	1.01	0.65	0.37
Stomach	1	0.25*	0.3*	0.36	0.18	0.07	-0.01
	2	0.67*	0.42*	0.4	0.27	0.15	0.05
	3	0.67*	0.49	0.38	0.25	0.14	0.07
Testis	1	0.06	0.01	0.03	-0.06	0.14*	0.09*
	2	0.31*	0.41*	0.18*	0.35*	0.15*	0.08*
	3	0.6*	0.25*	0.4*	0.34*	0.17*	0.08*
Urethra	N/A	0.87	0.69*	0.52*	0.35*	0.22	0.11*
Uterus	1	0.29	0.39	0.32	0.35	0.28	0.07
	2	1.15*	1.28	0.99	0.97	0.73	0.38
	3	0.89*	2.16	1.75	1.31	0.74	0.39
Vulva	1	0.17*	0.66	1.35	1.08	1.1	0.83
	2	2.35*	1.87*	1.54*	1.00*	0.67*	0.28*
	3	2.56*	1.97*	1.48*	1.00	0.62	0.27*

* indicates strata estimates of lower confidence whereby crude rather than net survival estimates were applied.

Supplementary Table 5: Attributable deaths in one year by tumour stage and age of diagnosis from delay to surgery of (a) 3 months (b) 6 months for 31 cancer types/subtypes.

Supplementary Table 5a	Stage	30-39 v	40-49 v	50-59 v	60-69 v	70-79 v	80+ v
Bladder	1	0.1*	1.0*	6.8	10.6	15.2	2.2
	2	0.1*	3.7	9.8	22.1	18.7	3.8
	3	0.5*	1.9*	4.6	11.5	12.3	3.4
Breast (ER+, HER2-)	1	0.9	1.7	0.0	0.0	0.0	0.0
	2	6.1	13.3	11.4	0.0	0.0	0.0
	3	4.4	11.2	12.9	10.9	6.3	1.2
Breast (ER-, HER2-)	1	1.3	2.2	4.6	0.3	0.9	1.6
	2	6.4	14.0	13.5	10.4	9.8	10.9
	3	1.9*	5.3	5.3	4.7	4.9	4*
Breast (HER2+)	1	0.1	0.6	0.3	0.0	0.0	1.4
	2	2.4	4.7	5.1	1.6	0.0	5.8
	3	2.5	3.6	5.1	3.3	4.6	3.5
Breast (other)	1	1.6	3.3	0.0	0.0	0.0	0.0
	2	6.2	11.3	10.7	1.2	0.0	0.0
	3	3.8	7.9	8.8	6.9	5.4	5.2
Cervix	1	4.3	4.2	0.7	3.4	0.9*	0.6*
	2	0.7*	2.5	0.8*	1.2	0.5*	0.4*
	3	0.3*	0.4*	0.4*	0.1*	0.1*	0.1*
Colon and rectosigmoid junction	1	0.2	1.1	3.2	4.5	0.0	0.0
	2	4.9	10.5	29.2	68.8	93.4	0.0
	3	13.0	26.9	76.3	144.8	184.5	121.9
Glioblastoma	N/A	10.8	16.5	20.5	18.7	17.6*	0.8*
Hypopharynx	N/A	0.1*	1.7*	7.9	12.1	6.8	1.5*
Kidney	1	0.7	2.8	11.9	11.6	0.0	0.0
	2	0.9*	4.5	5.3	9.7	5.5	3.4
	3	1.5*	9.1	24.6	37.3	30.9	8.4
Larynx	1	0.1*	0.8	3.6	6.1	3.3	3.3
	2	0.1*	0.7*	1.6*	4.6	4.1	2.3*
	3	0.2*	1.1*	4.2	6.9	5.1	2.1*
Liver	1	0.2*	0.9*	5.6	7.7	6.2	1.5*
	2	0.5*	1.1*	5.2	9.9	8.2	1.8*
	3	0.3*	0.8*	2*	3.9	4*	0.9*
Lung (non-small cell)	1	0.4	4.2	35.1	111.9	142.6	27.0
	2	1.1*	4.7	23.0	67.8	70.4	17.4
	3	0.9*	4.9	20.9	44.6	40.4	7.1
Lung (small cell)	1	0.0*	0.1*	0.7*	3.0	3*	0.6*
	2	0.0*	0.1*	0.5*	1.4*	1.4*	0.2*
	3	0.0*	0.0*	0.7*	1.7*	0.8*	0.1*
Melanoma of skin	1	1.6	6.7	1.0	4.6	0.0	5.6
	2	4.1	11.6	20.5	46.3	59.4	90.8
	3	3.9	8.5	14.0	18.8	18.2	16.0
Nasal cavity and sinus	N/A	0.4*	2.6*	3.8*	7.5	6.0	2.6*
Nasopharynx	N/A	0.0*	0.3*	0.9*	1.4*	0.9*	0.2*
Oesophagus	1	0.3*	1.7	5.6	11.5	6.9	1.1*
	2	0.1*	1.8*	9.4	20.3	13.8	1.6*
	3	0.7*	5.8	20.8	39.5	24.6	2.2*
Oral cavity	N/A	6.4	27.5	65.0	84.3	64.8	36.7
Oropharynx	N/A	1.4	16.8	44.1	45.0	22.0	6.2
Ovary	1	2.6	7.5	16.6	14.1	9.7	0.0
	2	0.7*	4.2	9.0	10.7	10.6	4.3
	3	4.8	21.6	49.1	72.7	53.7	11.1
Pancreas	1	0.0*	0.4*	0.7*	1.1	1.7*	0.3*
	2	0.5*	4.2*	12.4	23.2	20.7	4.5*
	3	0.2*	0.5*	1.5*	3.2*	2.0*	0.3*
Prostate	1	0.0*	0.3	0.0	0.0	0.0	1.2
	2	0.0*	0.0	0.0	0.0	0.0	0.9*
	3	0.0*	0.0	0.0	0.0	0.0	0.7*
Rectal	1	0.4	1.3	2.0	3.7	0.0	0.0
	2	1.2	3.4	10.8	25.2	20.1	1.9
	3	6.1	16.2	45.4	67.7	57.7	26.5
Renal pelvis and ureter	1	0.0*	0.1*	0.6*	3.2	7.8	2.3
	2	0.0*	0.3*	0.7*	4.0	6.1	1.0
	3	0.1*	0.3*	2.4*	9.2	17.1	7.2
Salivary glands	N/A	1.1	5.0	4.6	11.6	10.6	8.7
Stomach	1	0.2*	0.8*	3.1	4.4	3.3	0.0
	2	0.9*	1.7*	7.6	12.6	15.0	2.9
	3	0.9*	4.1	10.4	16.7	19.8	6.1
Testis	1	0.5	0.0	0.0	0.0	0.0*	0.0*
	2	0.3*	0.3*	0.1*	0.1*	0.0*	0.0*
	3	0.8*	0.2*	0.3*	0.2*	0.0*	0.0*
Urethra	N/A	0.0	0.0*	0.2*	0.7*	1.1	0.4*
Uterus	1	0.6	5.4	23.9	54.3	53.3	4.7
	2	0.2*	1.8	6.3	14.8	18.4	9.2
	3	0.1*	4.2	17.5	34.9	35.2	16.5
Vulva	1	0.1*	0.8	4.0	5.1	10.6	19.1
	2	0.1*	0.3*	0.8*	1.2*	1.6*	2.0*
	3	0.4*	1.3*	2.4*	4.4	6.3	5.0*

* indicates strata estimates of lower confidence whereby crude rather than net survival estimates were applied.

Supplementary Table 5b	Stage	30-39 v	40-49 v	50-59 v	60-69 v	70-79 v	80+ v
Bladder	1	0.2*	2.5*	16.2	26.7	37.8	5.6
	2	0.2*	7.5	22.2	51.6	48.9	8.8
	3	1.1*	3.7*	9.9	22.9	25.8	6.9
Breast (ER+, HER2-)	1	2.3	6.2	0.0	0.0	0.0	0.0
	2	14.0	33.1	36.9	9.4	0.0	0.0
	3	9.6	25.9	30.8	29.4	22.8	5.8
Breast (ER-, HER2-)	1	3.1	5.2	11.9	6.0	3.9	3.8
	2	14.1	31.5	31.4	27.5	28.0	23.5
	3	3.9*	10.6	11.0	10.2	10.6	7.8*
Breast (HER2+)	1	0.3	1.9	3.5	1.4	0.9	3.4
	2	5.6	11.7	14.8	10.8	7.7	13.3
	3	5.6	8.3	12.1	9.0	12.6	8.2
Breast (other)	1	3.9	8.9	0.0	0.0	0.0	0.0
	2	14.3	27.5	30.5	19.6	3.5	0.0
	3	8.3	17.9	20.6	18.0	16.7	13.4
Cervix	1	11.4	11.3	2.1	8.7	2.5*	1.3*
	2	1.8*	5.3	2.1*	3.0	1.3*	0.9*
	3	0.7*	0.9*	1.0*	0.2*	0.3*	0.2*
Colon and rectosigmoid junction	1	0.5	2.9	9.3	20.1	0.0	0.0
	2	12.2	26.6	76.0	186.1	275.7	65.3
	3	29.9	62.8	180.5	358.9	465.9	294.9
Glioblastoma	N/A	15.7	20.6	23.7	20.5	19.5*	0.8*
Hypopharynx	N/A	0.3*	3.1*	13.4	20.6	11.2	2.6*
Kidney	1	1.9	7.8	33.2	38.4	1.8	0.0
	2	2.2*	11.3	14.0	25.8	16.7	9.0
	3	3.8*	22.0	59.2	91.9	80.6	23.9
Larynx	1	0.3*	2.0	9.0	16.2	10.9	10.1
	2	0.2*	1.7*	4*	10.5	9.3	4.4*
	3	0.5*	2.5*	8.7	15.0	11.3	3.3*
Liver	1	0.6*	2*	12.1	16.0	12.6	3.4*
	2	1.0*	2.6*	9.7	19.3	16.0	3.5*
	3	0.5*	1.4*	3.6*	6.8	6.7*	1.5*
Lung (non-small cell)	1	1.1	10.7	84.7	269.7	344.3	75.7
	2	2.5*	10.2	49.4	142.0	144.7	34.2
	3	1.7*	9.5	39.1	77.9	71.7	11.2
Lung (small cell)	1	0.0*	0.1*	1.5*	5.9	6*	1.3*
	2	0.0*	0.2*	0.9*	2.5*	2.4*	0.4*
	3	0.0*	0.0*	1.1*	2.8*	1.2*	0.2*
Melanoma of skin	1	4.4	17.7	3.1	13.8	2.1	18.8
	2	10.1	28.2	49.7	109.1	143.7	198.9
	3	9.1	19.5	32.1	42.1	44.1	32.8
Nasal cavity and sinus	N/A	1.1*	5.9*	8.2*	15.0	11.7	4.6*
Nasopharynx	N/A	0.0*	0.8*	1.9*	2.7*	1.7*	0.4*
Oesophagus	1	0.6*	4.0	13.3	28.1	17.9	2.5*
	2	0.3*	3.5*	19.5	42.8	30.8	3*
	3	1.4*	10.7	35.9	73.0	43.3	3.9*
Oral cavity	N/A	15.4	62.2	145.7	188.1	142.5	82.6
Oropharynx	N/A	3.5	40.6	107.8	107.9	51.0	12.0
Ovary	1	6.9	19.8	43.4	38.0	27.5	0.0
	2	1.8*	10.1	21.0	25.0	24.3	9.1
	3	10.9	42.6	90.0	128.1	91.3	17.1
Pancreas	1	0*	1*	2.1*	3.4	4.7*	0.8*
	2	1.1*	8.4*	20.2	36.6	32.7	7.9*
	3	0.5*	1.3*	3.4*	6.1*	4*	0.5*
Prostate	1	0.0*	0.9	0.0	0.0	4.4	3.0
	2	0.0*	0.0	0.0	0.0	0.0	2.1*
	3	0.0*	0.0	0.0	0.0	0.0	1.5*
Rectal	1	1.2	3.4	7.9	25.3	0.3	3.6
	2	3.0	8.9	29.5	74.8	77.8	15.2
	3	14.6	38.6	114.0	181.5	170.1	71.3
Renal pelvis and ureter	1	0.0*	0.3*	1.6*	8.3	19.1	6.5
	2	0.0*	0.8*	1.7*	9.1	14.0	3.5
	3	0.3*	0.7*	5.5*	18.0	31.9	15.4
Salivary glands	N/A	2.9	12.2	12.3	28.6	26.7	18.6
Stomach	1	0.6*	2*	7.3	12.2	11.6	0.0
	2	1.7*	4*	16.0	26.3	34.1	8.6
	3	2*	7.3	19.0	31.0	36.4	11.4
Testis	1	1.5	0.2	0.4	0.0	0.4*	0.2*
	2	0.7*	0.7*	0.2*	0.2*	0*	0*
	3	1.8*	0.5*	0.7*	0.4*	0.1*	0*
Urethra	N/A	0.0	0.1*	0.4*	1.2*	2.1	0.8*
Uterus	1	1.6	14.4	65.3	151.0	153.6	25.5
	2	0.6*	4.5	15.9	35.7	41.8	21.0
	3	0.3*	9.5	38.7	69.9	64.3	31.2
Vulva	1	0.1*	2.0	10.2	13.2	25.9	39.9
	2	0.1*	0.7*	1.8*	2.7*	3.5*	3.4*
	3	0.8*	2.8*	5.2*	7.8	11.3	8.3*

* indicates strata estimates of lower confidence whereby crude rather than net survival estimates were applied.

Supplementary References

1. *National life tables: UK 2016-2018*. Office for National Statistics.
2. *England and Wales 2011 Census*. 2011, Office for National Statistics.
3. *World Population Ageing 2019*. 2019, United Nations.
4. Davies, N.G., et al., *The effect of non-pharmaceutical interventions on COVID-19 cases, deaths and demand for hospital services in the UK: a modelling study*. medRxiv, 2020.
5. *National Cancer Registration and Analysis Service (NCRAS)*. 2018, Public Health England.
6. *CAS-SOP #4.5 Linking treatment tables – chemotherapy, tumour resections and radiotherapy version 4.5*. 2018, Public Health England.
7. Lee, Y.H., et al., *Effect of length of time from diagnosis to treatment on colorectal cancer survival: A population-based study*. PLoS One, 2019. **14**(1): p. e0210465.
8. Richards, M.A., et al., *Influence of delay on survival in patients with breast cancer: a systematic review*. Lancet, 1999. **353**(9159): p. 1119-26.
9. Mano, R., et al., *The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm*. Urologic Oncology: Seminars and Original Investigations, 2016. **34**(5): p. 239.e1-239.e8.
10. Smith, E.C., A. Ziogas, and H. Anton-Culver, *Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race/Ethnicity*. JAMA Surgery, 2013. **148**(6): p. 516-523.
11. Chu, A.T., et al., *Delays in radical cystectomy for muscle-invasive bladder cancer*. Cancer, 2019. **125**(12): p. 2011-2017.
12. Sánchez-Ortiz, R.F., et al., *An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma*. The Journal of urology, 2003. **169**(1): p. 110-5; discussion 115.
13. May, M., et al., *Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder*. Scandinavian Journal of Urology and Nephrology, 2004. **38**(3): p. 231-235.
14. Bleicher, R.J., et al., *Time to Surgery and Breast Cancer Survival in the United States*. JAMA Oncology, 2016. **2**(3): p. 330-339.
15. Samson, P., et al., *Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer*. The Annals of Thoracic Surgery, 2015. **99**(6): p. 1906-1913.
16. Yang, C.-F.J., et al., *Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma*. CHEST, 2017. **152**(6): p. 1239-1250.
17. Richards, M.A., et al., *The influence on survival of delay in the presentation and treatment of symptomatic breast cancer*. British journal of cancer, 1999. **79**(5-6): p. 858-864.
18. *The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)*. 2020, China CCDC.
19. *Updated Intercollegiate General Surgery Guidance on COVID-19*. 2020, Royal College of Surgeons England.
20. Grasselli, G., et al., *Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy*. Jama, 2020.
21. *ICNARC report on COVID-19 in critical care*. 2020.
22. *Hospital Admitted Patient Care Activity*. 2020, NHS Digital.